Authors
Latest:
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Radical nephrectomy before or after systemic therapy for mRCCRecent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Latest:
How text messaging can be a valuable tool for your practiceHere are seven ways texting can improve healthcare revenue and decrease costs.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
New Drug Application initiated with FDA for TAR-200 for NMIBCThe NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
Latest:
Online reviews are crucial to maintaining a thriving health care practiceIndependent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
Latest:
Managing your online reputation in health careWhile online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Latest:
Dayna R. Smerina and Amy M. Pearlman, MD, discuss their research in sexual medicineSmerina and Pearlman discuss recent research collaborations in the field of sexual medicine.
Latest:
The importance of PSADT in high-risk, biochemically recurrent prostate cancer"We need to be aware that patients have options for treatment of high-risk biochemical recurrence, and in order to identify that they have high-risk biochemical recurrence...we need to calculate PSA doubling time,” says Alicia Morgans, MD, MPH.
Latest:
Neoadjuvant chemoimmunotherapy combo shows promise in UTUCThe phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Latest:
Register Today! UH Urology Institute’s Fall SymposiumsUniversity Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
Latest:
Robert Svatek, MD, discusses the design of the PIVOT-006 trial“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.
Latest:
Desai Sethi Urology Institute shares inaugural Annual ReportThe report, titled "TRANSFORMATION: From an academic department to a leading Institute," highlights DSUI's transformation from a department into a multidisciplinary institute.
Latest:
Allina Health Cancer Institute 2022 Symposium reimagines cancer careThe symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Tobias Nordström, MD, on the evolving landscape of prostate cancer screening“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias Nordström, MD, PhD.
Latest:
Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Ralph Miller, MD, on the state of HIFU in prostate cancer"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.
Latest:
Abiraterone-based triplet boosts survival in de novo mCSPCFindings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest:
Episode 3 Video: Treatment Strategies to Tackle NMIBC HeterogeneityPanelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
The aging surgeon: A geriatrician's perspective"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Novel intravesical drug delivery systems explored in bladder cancer"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
Latest:
Expert advice on improving interactions with difficult patients“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Latest:
Christina Ching, MD, on overcoming barriers to follow-up after pediatric stone surgery“We might need to do a better job in general about education of the importance of follow-up,” says Christina B. Ching, MD.
